Pediatrix Medical Group (NYSE:MD – Get Free Report) posted its quarterly earnings data on Friday. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07, Briefing.com reports. The business had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. Pediatrix Medical Group had a positive return on equity of 10.59% and a negative net margin of 12.58%. The company’s revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.29 earnings per share.
Pediatrix Medical Group Trading Up 23.5 %
MD opened at $15.21 on Friday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.38 and a current ratio of 1.38. Pediatrix Medical Group has a one year low of $6.62 and a one year high of $15.42. The company has a market cap of $1.31 billion, a P/E ratio of -5.02, a PEG ratio of 1.96 and a beta of 1.56. The business’s 50-day simple moving average is $11.54 and its 200-day simple moving average is $9.36.
Wall Street Analysts Forecast Growth
Several research firms recently commented on MD. Jefferies Financial Group raised Pediatrix Medical Group from a “hold” rating to a “buy” rating and boosted their target price for the stock from $8.00 to $14.00 in a research note on Thursday, September 26th. Truist Financial boosted their price objective on Pediatrix Medical Group from $10.00 to $13.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. StockNews.com raised shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a report on Wednesday, August 7th. Finally, UBS Group lifted their price target on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a research note on Friday, August 9th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $10.90.
Insider Buying and Selling
In other news, CEO James D. Swift sold 11,100 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $10.79, for a total value of $119,769.00. Following the completion of the transaction, the chief executive officer now owns 170,001 shares in the company, valued at approximately $1,834,310.79. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Pediatrix Medical Group news, CFO C Marc Richards sold 17,438 shares of Pediatrix Medical Group stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $10.08, for a total transaction of $175,775.04. Following the transaction, the chief financial officer now owns 175,347 shares of the company’s stock, valued at $1,767,497.76. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO James D. Swift sold 11,100 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $10.79, for a total value of $119,769.00. Following the completion of the sale, the chief executive officer now owns 170,001 shares of the company’s stock, valued at approximately $1,834,310.79. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 68,100 shares of company stock worth $701,889 over the last 90 days. 2.00% of the stock is owned by insiders.
Pediatrix Medical Group Company Profile
Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.
Featured Stories
- Five stocks we like better than Pediatrix Medical Group
- What Are Dividends? Buy the Best Dividend Stocks
- Battle of the Retailers: Who Comes Out on Top?
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- How to Invest in the Best Canadian Stocks
- MarketBeat Week in Review – 10/28 – 11/1
Receive News & Ratings for Pediatrix Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediatrix Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.